Age Determines Adjuvant Chemotherapy Use in Resected Stage II Colon Cancer

Area of Science:

• Oncology
• Clinical Research
• Cancer Treatment

Background:

• The role of adjuvant chemotherapy in resected stage II colon cancer is debated.
• Treatment decisions often hinge on identifying high-risk features for recurrence.

Purpose of the Study:

• To identify differences in early-onset versus late-onset colorectal cancer.
• To determine if these differences impact treatment decisions, particularly adjuvant chemotherapy.
• To test the hypothesis that high-risk features in stage II colorectal cancer differ by age and influence chemotherapy use.

Main Methods:

• Retrospective cohort study utilizing the National Cancer Database.
• Patients with resected stage II colon cancer were stratified into young (≤45), middle-aged (50-75), and older (>75) age groups.
• Analysis focused on the incidence of high-risk clinicopathologic features and receipt of adjuvant chemotherapy.

Main Results:

• Of 14,966 patients, young patients (44%) had high-risk features slightly more often than middle-aged (40%) and older (42%) patients.
• Adjuvant chemotherapy was received by 56% of young patients, 30% of middle-aged patients, and only 7% of older patients.
• Age group was an independent predictor of receiving adjuvant chemotherapy, even after controlling for other factors.

Conclusions:

• Younger patients frequently receive adjuvant chemotherapy for stage II colon cancer, irrespective of risk status.
• Older patients are significantly underrepresented in adjuvant chemotherapy use.
• Oncologists must be mindful of age-related disparities in treatment and avoid age as the sole determinant for chemotherapy decisions.